Branched-chain amino acids
Biomarker4 papers2 findings
- Human trial1
- Humans2
Interventions
1Glimepiride
downin humans1Moderate certainty
1 study
Glimepiride
downin humans1Moderate certainty
Glimepiride decreases branched-chain amino acids in humans.
Human trialtype 2 diabetes and biopsy-confirmed MASLDliver48 weeks
Distinct metabolomic signatures of SGLT2 inhibitor vs. sulfonylurea in a paired human liver biopsy study · Biochemistry and biophysics reports · 14 Sep 2026
Associations
1Sarcopenic obesity
upin humans1OR 1.555–1.693
1 study
Sarcopenic obesity
upin humans1OR 1.555–1.693
Branched-chain amino acids raise the risk of sarcopenic obesity in humans (ORs: 1.555-1.693, P < 0.01).
Humans14 years
Divergent amino acid profiles in sarcopenic obesity versus non-obese sarcopenia: A prospective cohort study in community-dwelling older adults · The journal of nutrition, health & aging · 11 Sep 2026
Latest
10BMC Pharmacology & ToxicologyModel organisms
Assessing the toxicological effects of synthetic musk ketone using the Caenorhabditis elegans model
Biochemistry and Biophysics ReportsHuman trial
Distinct metabolomic signatures of SGLT2 inhibitor vs. sulfonylurea in a paired human liver biopsy study
The Journal of Nutrition, Health & AgingHumans
Divergent amino acid profiles in sarcopenic obesity versus non-obese sarcopenia: A prospective cohort study in community-dwelling older adults
Frontiers in EndocrinologyHumans